The MMS Experience

We are one team with one purpose – to positively improve lives worldwide.

At MMS, regardless of where our colleagues are located around the world, we are one team with one purpose – to positively improve lives worldwide. #OneMMS is more than just a hashtag. It’s a promise that our organization embraces the unique strengths and experiences of colleagues, providing everyone the opportunity to fortify and grow their talents, as well as enjoy dynamic career opportunities in life sciences.

DIVERSITY

Our global footprint provides MMS colleagues the opportunity to experience many different cultures and backgrounds, resulting in a work environment focused on inclusion and mutual respect. We celebrate and continuously welcome diversity to our team, and we keep diversity, equity, and inclusion (DEI) top of mind as we build global engagement activities, implement new processes, and innovative technology, open new positions, and offer new leadership opportunities.

TEAMWORK

We are committed to helping our colleagues achieve a common goal – making a positive impact on patients’ lives and the lives of their families. For each project we undertake, our team promotes flexible planning to assess subject matter expertise, process optimization, and risk planning for any project to ensure on-time delivery and added value to each client.

FLEXIBILITY & ADAPTABILITY

Our innovation-first, Kaizen culture allows us to embrace change, pioneer new processes and technologies, and work on continual improvement in every aspect of our business. Colleagues, at any level in our organization can propose improvements and see their suggestions come to fruition with our culture of continual, proven improvement.

OUR CLIENTS

Working at MMS gives our global colleagues a unique opportunity to work with a variety of industry-leading clients, therapeutic areas, drug development phases, and projects in the pharmaceutical, biotechnology, and medical device industries. Our extensive training, leadership, and mentor programs give colleagues from all backgrounds and experience levels the opportunity to learn.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization